Do β2 microglobulin levels affect survival of newly diagnosed myeloma patients with translocation t(4;14) or 17p13 deletion treated with conventional chemotherapy?

被引：2
|
作者：
Chng, W. J. [1 ]
Jacobus, S. [2 ]
Fonseca, R. [1 ]
机构：
[1] Mayo Clin, Comprehens Canc Ctr, Scottsdale, AZ USA
[2] Dana Faber Canc Inst, Eastern Coop Oncol Grp Stat Ctr, Boston, MA USA
来源：
LEUKEMIA | 2008年 / 22卷 / 05期
关键词：
D O I：
10.1038/sj.leu.2405009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1080 / 1081
页数：3
相关论文
共 41 条
  • [21] Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT
    Gagelmann, Nico
    Eikema, Diderik-Jan
    de Wreede, Liesbeth C.
    Rambaldi, Alessandro
    Iacobelli, Simona
    Koster, Linda
    Caillot, Denis
    Blaise, Didier
    Rememyi, Peter
    Bulabois, Claude-Eric
    Passweg, Jakob
    Leleu, Xavier
    Zver, Samo
    Kobbe, Guido
    Ljungman, Per
    Chevallier, Patrice
    Ringhoffer, Mark
    Martin, Murray
    Salmenniemi, Urpu
    Poire, Xavier
    Lenhoff, Stig
    Pioltelli, Pietro
    Mordini, Nicola
    Delforge, Michel
    Garderet, Laurent
    Schoenland, Stefan
    Yakoub-Agha, Ibrahim
    Kroeger, Nicolaus
    BONE MARROW TRANSPLANTATION, 2021, 56 (01) : 210 - 217
  • [22] Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis
    Amro M. S. El-Ghammaz
    Essam Abdelwahed
    Annals of Hematology, 2016, 95 : 1315 - 1321
  • [23] Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT
    Nico Gagelmann
    Diderik-Jan Eikema
    Liesbeth C. de Wreede
    Alessandro Rambaldi
    Simona Iacobelli
    Linda Koster
    Denis Caillot
    Didier Blaise
    Péter Remémyi
    Claude-Eric Bulabois
    Jakob Passweg
    Xavier Leleu
    Samo Zver
    Guido Kobbe
    Per Ljungman
    Patrice Chevallier
    Mark Ringhoffer
    Murray Martin
    Urpu Salmenniemi
    Xavier Poiré
    Stig Lenhoff
    Pietro Pioltelli
    Nicola Mordini
    Michel Delforge
    Laurent Garderet
    Stefan Schönland
    Ibrahim Yakoub-Agha
    Nicolaus Kröger
    Bone Marrow Transplantation, 2021, 56 : 210 - 217
  • [24] Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16)
    Duek, Adrian
    Trakhtenbrot, Luba
    Amariglio, Ninette
    Benyamini, Noam
    Zilbershats, Itay
    Ganzel, Chezi
    Shevetz, Olga
    Leiba, Ronit
    Rozic, Gabriela
    Nagler, Arnon
    Leiba, Merav
    GENES CHROMOSOMES & CANCER, 2019, 58 (08): : 516 - 520
  • [25] Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and-17p13 in myeloma patients treated with high-dose therapy
    Gertz, MA
    Lacy, MQ
    Dispenzieri, A
    Greipp, PR
    Litzow, MR
    Henderson, KJ
    Van Wier, SA
    Ahmann, GJ
    Fonseca, R
    BLOOD, 2005, 106 (08) : 2837 - 2840
  • [26] Conventional Cytogenetics and FISH [del13q, del17p, t(11;14), t(4;14)] Findings and Their Relationship with Other Risk Factors in Multiple Myeloma
    Balcik, Ozlem S.
    Albayrak, Murat
    Dagdas, Simten
    Helvaci, Nafiye
    Yokus, Osman
    Ceran, Funda
    Ozet, Gulsum
    Ergocen, Salih
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2011, 21 (04): : 203 - 209
  • [27] Two novel fibroblast growth factor receptor 3 (FGFR3) mutations in newly diagnosed multiple myeloma patients with and without the t(4;14) translocation.
    Soverini, S
    Terragna, C
    Martinelli, G
    Ruggeri, D
    Testoni, N
    Ottaviani, E
    Amabile, M
    Giannini, B
    Buonamici, S
    Zamagni, E
    Cellini, C
    Tosi, P
    Cavo, M
    Tura, S
    Baccarani, M
    BLOOD, 2001, 98 (11) : 572A - 572A
  • [28] Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group
    Grzasko, Norbert
    Hajek, Roman
    Hus, Marek
    Chocholska, Sylwia
    Morawska, Marta
    Giannopoulos, Krzysztof
    Czarnocki, Krzysztof
    Druzd-Sitek, Agnieszka
    Pienkowska-Grela, Barbara
    Rygier, Jolanta
    Usnarska-Zubkiewicz, Lidia
    Dytfeld, Dominik
    Kubicki, Tadeusz
    Jurczyszyn, Artur
    Korpysz, Maciej
    Dmoszynska, Anna
    LEUKEMIA & LYMPHOMA, 2017, 58 (09) : 2089 - 2100
  • [29] Impact of Chromosomal Abnormalities Del(13), T(4;14), and Del(17p) and Prior Treatment on Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Lenalidomide.
    Loiseau, Herve Avet
    Soulier, Jean
    Fermand, Jean-Paul
    Facon, Thierry
    Attal, Michel
    Harousseau, Jean-Luc
    Belhadj, Karim
    Hulin, Cyril
    Garderet, Laurent
    Dorvaux, Veronique
    Moreau, Philippe
    BLOOD, 2008, 112 (11) : 1262 - 1262
  • [30] No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades
    Chalopin, Thomas
    Vallet, Nicolas
    Theisen, Olivier
    Ochmann, Marlene
    Tiab, Mourad
    Godmer, Pascal
    Barin, Carole
    Herault, Olivier
    Gyan, Emmanuel
    Le Gouill, Steven
    Avet-Loiseau, Herve
    Benboubker, Lotfi
    Moreau, Philippe
    Touzeau, Cyrille
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (03) : 635 - 638
12345